OPKO Health, Inc. Proceeds from Long-term Lines of Credit
OPKO Health, Inc. (OPK) reported Proceeds from Long-term Lines of Credit of $15.35 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2013-08-09
- OPKO Health, Inc. proceeds from long-term lines of credit for the quarter ending 2013-06-30 was $6.93M, a 38.25% decline year-over-year.
- OPKO Health, Inc. proceeds from long-term lines of credit for the quarter ending 2013-03-31 was $8.43M, a 18.47% decline year-over-year.
- OPKO Health, Inc. proceeds from long-term lines of credit for the quarter ending 2012-12-31 was $7.12M, a 35.72% increase year-over-year.
- OPKO Health, Inc. proceeds from long-term lines of credit for the quarter ending 2012-09-30 was $7.84M, a 82.06% increase year-over-year.
- OPKO Health, Inc. proceeds from long-term lines of credit for fiscal 2012 was $36.51M, a 138.60% increase from fiscal 2011.
- OPKO Health, Inc. proceeds from long-term lines of credit for fiscal 2011 was $15.30M, a 0.80% decline from fiscal 2010.
- OPKO Health, Inc. proceeds from long-term lines of credit for fiscal 2010 was $15.42M, a 2815.69% increase from fiscal 2009.
- OPKO Health, Inc. proceeds from long-term lines of credit for fiscal 2009 was $529.00K.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2013-06-30 | $6.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $15.35M 10-Q · filed 2013-08-09 | $22.47M derived: sum of 3 quarters · filed 2013-08-09 | $30.31M derived: sum of 4 quarters · filed 2013-08-09 |
| 2013-03-31 | $8.43M 10-Q · filed 2013-05-10 | $15.54M derived: sum of 2 quarters · filed 2013-05-10 | $23.38M derived: sum of 3 quarters · filed 2013-05-10 | $34.60M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $14.95M derived: sum of 2 quarters · filed 2013-03-18 | $26.17M derived: sum of 3 quarters · filed 2013-08-09 | $36.51M 10-K · filed 2013-03-18 |
| 2012-09-30 | $7.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $19.05M derived: sum of 2 quarters · filed 2013-08-09 | $29.39M 10-Q · filed 2012-11-09 | $34.63M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-06-30 | $11.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $21.55M 10-Q · filed 2013-08-09 | $26.80M derived: sum of 3 quarters · filed 2013-08-09 | $31.10M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-03-31 | $10.34M 10-Q · filed 2013-05-10 | $15.58M derived: sum of 2 quarters · filed 2013-05-10 | $19.89M derived: sum of 3 quarters · filed 2013-05-10 | $22.61M derived: sum of 4 quarters · filed 2013-05-10 |
| 2011-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $9.55M derived: sum of 2 quarters · filed 2013-03-18 | $12.27M derived: sum of 3 quarters · filed 2013-03-18 | $15.30M 10-K · filed 2013-03-18 |
| 2011-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $7.03M derived: sum of 2 quarters · filed 2012-11-09 | $10.06M 10-Q · filed 2012-11-09 | $20.00M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $5.75M 10-Q · filed 2012-08-09 | $15.70M derived: sum of 3 quarters · filed 2013-03-18 | $17.68M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $3.03M 10-Q · filed 2012-05-10 | $12.97M derived: sum of 2 quarters · filed 2013-03-18 | $14.95M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $11.92M derived: sum of 2 quarters · filed 2013-03-18 | $15.42M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $5.48M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $3.50M 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | $529.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |